^
Association details:
| Biomarker: | MYD88 L265P |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | KT-413 (IKZF1 degrader, IKZF3 degrader, IRAK-4 degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
2088 Ktx-120, a Novel Irakimid Degrader of IRAK4 and IMiD Substrates Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL CDX and PDX Models
Published date:
11/04/2020
Excerpt:
In the OCI-Ly10 ABC DLBCL cell line that harbors a MYD88L265P mutation, the cell activity of KTX-120 was associated with degradation of both IRAK4 and Ikaros, supporting the combined IRAK4 and IMiD targeting of this molecule as contributing to cell activity.
